Drugmakers Plan 2026 U.S. Price Increases on Over 350 Branded Medications Despite Political Pressure 
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
Boeing Secures Major $2.7 Billion U.S. Military Contract for Apache Helicopter Support 
Bain Capital Moves to Acquire Majority Stake in Echo Marketing 
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
Neuralink Plans High-Volume Brain Implant Production and Fully Automated Surgery by 2026 
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Uppsala, Sweden, March 30, 2016 -- Oasmia Pharmaceutical AB (NASDAQ: OASM), a developer of a new generation of drugs within human and veterinary oncology, announced today that the first patient has been enrolled in the Phase I clinical study of the Company's next-generation cancer treatment candidate Docecal, to be performed internationally. Docecal was approved for clinical trials in December, 2015.
Docecal is a nanoparticle and water-soluble formulation of docetaxel, one of the most commonly used anti-cancer substances in oncology today, in combination with the Company's patented technology XR17. A standard treatment for multiple cancers including prostate, breast, lung and stomach, docetaxel is the most active substance in the cytostatic Taxotere(r), marketed by the global healthcare provider Sanofi-Aventis. Prior to the patent expiration in 2010, Sanofi-Aventis executed $3 billion in Taxotere sales 2009. Taxotere has continued to perform well.
About Docecal
Docecal is a water soluble formulation of docetaxel in combination with Oasmia's patented technology XR17. Docetaxel is standard treatment for a variety of different kinds of cancers, such as prostate cancer, breast cancer, lung cancer and stomach cancer.
About Oasmia Pharmaceutical AB
Oasmia Pharmaceutical AB develops, manufactures, markets and sells new generations of drugs in the field of human and veterinary oncology. The company's product development aims to create and manufacture novel nanoparticle formulations and drug-delivery systems based on well-established cytostatics which, in comparison with current alternatives, show improved properties, reduced side-effects, and expanded applications. The company's product development is based on its proprietary in-house research and company patents. Oasmia is listed on NASDAQ Capital Markets (OASM.US), Frankfurt Stock Exchange (OMAX.GR, ISIN SE0000722365) and NASDAQ Stockholm (OASM.ST).
Julian Aleksov, Executive Chairman
Tel: +46 18 50 54 40
E-mail: [email protected]
For media relations:
Eric Fischgrund
Tel: +1 646 699 1414
E-mail: [email protected]
